2-Ethynyl-L-ornithine | 67605-54-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Ethynyl-L-ornithine
• 英文别名: (2R)-2,5-diamino-2-ethynylpentanoic acid
• CAS: 67605-54-3
• 化学式: C₇H₁₂N₂O₂
• 分子量: 156.18
• InChiKey: JWWZUFCRQMJENK-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.5
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  89.3
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• S-Adenosylmethionine decarboxylase inhibitors
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0351475A1

  公开（公告）日：1990-01-24

  This invention relates to novel chemical compounds useful as S-adenosylmethionine decarboxylase inhibitors, of the formula H₂N-Q--Al wherein Al represents 5'-deoxyadenosyl.      represents adenosinyl, R represents H, methyl or ethyl and Q represents moieties of formulae Ia to If depicted as follows: wherein R₁ is H or F, n is 1 or 2, V₁ is H or CH₃, V₂ is H or COOH, and each of W, X, Y, and Z are H, F, Cl or Br. To the processes useful for their preperation and to their use in the treatment of a variety of condition and disease states associated with a rapid proliferation of cell growth.

  这项发明涉及一种新型化合物，可用作S-腺苷甲硫氨酸脱羧酶抑制剂，其化学式为H₂N-Q--Al，其中Al代表5'-去氧腺苷基。     代表腺苷基，R代表H、甲基或乙基，Q代表如下所示的化学式Ia至If的基团：其中R₁为H或F，n为1或2，V₁为H或CH₃，V₂为H或COOH，而W、X、Y和Z中的每一个均为H、F、Cl或Br。还涉及用于其制备的方法以及它们在治疗与细胞增殖快速增加相关的各种疾病和病症中的应用。
• D-enantiomer of DFMO and methods of use therefor
  申请人：ILEX Oncology, Inc.

  公开号：US20020045663A1

  公开（公告）日：2002-04-18

  The present invention concerns a method for preventing and/or treating cancer in a patient comprising administering an effective amount of substantially purified D enantiomer of difluoromethylornithine (D-DFMO) or an analog of D-DFMO to the patient. D-DFMO or an analog thereof is administered at a dose of about 0.05 to about 20.0 gm/M 2 /day. D-DFMO or an analog thereof may be administered more than once for the treatment and/or prevention of cancer. Methods of administration as well as compositions and formulations of substantially purified D-DFMO and analogs of D-DFMO are described.

  本发明涉及一种预防和/或治疗患者癌症的方法，包括向患者施用有效量的基本纯化的二氟甲基鸟氨酸D对映体（D-DFMO）或D-DFMO类似物。D-DFMO或其类似物的给药剂量约为0.05至约20.0 gm/M 2 /天。D-DFMO或其类似物可多次给药，用于治疗和/或预防癌症。本文描述了基本纯化的 D-DFMO 和 D-DFMO 类似物的给药方法以及组合物和制剂。
• Topical composition for follicular delivery of an ornithine decarboxylase inhibitor
  申请人：——

  公开号：US20030053973A1

  公开（公告）日：2003-03-20

  Polyethylene glycol ethers of alkyl alcohols having the general formula CH 3 (CH 2 ) x CH 2 (OCH 2 CH 2 ) n OH wherein x is 8 to 20 (of which ceteareth-20, steareth-20 and steareth-100 are preferred), poloxamer 185, poloxamer 407, N,N-dimethyl dodecylamine N-oxide, and mixtures thereof, are employed to increase follicular delivery and/or follicular residence time of certain water soluble ornithine decarboxylase inhibitors of which 2(difluoromethyl)-2,5-diamino pentanoic acid and its pharmaceutically acceptable salts, hydrates, optical enantiomers and racemic mixture are preferred.

  通式为 CH 3 (CH 2 ) x CH 2 (OCH 2 CH 2 ) n OH，其中 x 为 8 至 20（优选 ceteareth-20、steareth-20 和 steareth-100）、poloxamer 185、poloxamer 407、N,N-二甲基十二胺 N-氧化物及其混合物、可用于增加某些水溶性鸟氨酸脱羧酶抑制剂的毛囊递送和/或毛囊停留时间，其中优选 2（二氟甲基）-2,5-二氨基戊酸及其药学上可接受的盐、水合物、光学对映体和外消旋混合物。
• EP0198893A4
  申请人：——

  公开号：EP0198893A4

  公开（公告）日：1988-05-10
• HAIR GROWTH MODIFICATION
  申请人：HANDELMAN, Joseph H.

  公开号：EP0198893A1

  公开（公告）日：1986-10-29